Company intelligence / Profile preview

Vilya International

Seattle, Washington, United Stateshk.linkedin.com ↗

Ownership: Private
Employees: ~47
Development stage: Other

Overview

Vilya uses a proprietary AI-driven computational platform to design novel macrocyclic peptides and artificial amino acid-based drugs that are membrane-permeable and highly selective for challenging protein targets. The company’s approach enables targeting previously undruggable proteins across a broad range of disease areas. As of mid–2025, all programs are in preclinical stages with no reported clinical results yet.

Therapeutic areas: Other
Modalities: Macrocyclic peptidesPeptidesSmall moleculeAntibodyArtificial amino acid-based drugs
Industry: Biotech

Beyond the preview

Go deeper on Vilya International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vilya International.

Explore the full profile